Efficacy and safety of neoadjuvant sintilimab monotherapy versus sintilimab combined with epirubicin/ifosfamide in patients with surgically resectable retroperitoneal dedifferentiated liposarcoma: an open-label, randomized, two arms phase 2 trial
Latest Information Update: 03 Feb 2020
At a glance
- Drugs Epirubicin (Primary) ; Sintilimab (Primary) ; Ifosfamide
- Indications Liposarcoma
- Focus Therapeutic Use
- 03 Feb 2020 New trial record